StockNews.AI
MRK
StockNews.AI
175 days

Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky

1. Lawsuit alleges securities fraud over Gardasil $11B revenue forecast. Investors claim misrepresentation. 2. Defendants forecasted strong growth in China, later revised due to inventory issues. Data was misleading. 3. Merck stock fell over 9% in one day following the news. Investor losses occurred. 4. The class action covers February 3, 2022 to February 3, 2025. Affected shareholders are urged to join.

5m saved
Insight
Article

FAQ

Why Bearish?

The lawsuit claims misrepresentations that led to a dramatic stock drop, reminiscent of past cases where legal issues triggered selloffs. Historical examples include similar pharmaceutical lawsuits resulting in quick declines in share price.

How important is it?

The lawsuit directly challenges critical revenue expectations and has already impacted the stock significantly, making it highly important. Ongoing litigation could sustain investor uncertainty and affect valuations.

Why Short Term?

Immediate investor reactions and legal uncertainties are causing near-term volatility, as seen by the 9% drop. Such litigation events typically influence short-term sentiment until resolved.

Related Companies

PFEJNJ
NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=131766&wire=4 MRK investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Merck's expected revenue of $11 billion from sales of Gardasil by 2030. Defendants' statements included, among other things, confidence in Merck's purported ability to utilize successful consumer activation and education efforts on the benefits of Gardasil in order to drive demand and capitalize on eligible populations for vaccination, resulting in confidently optimistic reports and forecasts of Gardasil's growth in China.  The full truth finally emerged on February 4, 2025, when Merck announced it would no longer achieve the long-forecasted $11 billion in sales of Gardasil by 2030, as it would cease shipments of Gardasil to China "through at least midyear" to facilitate a "rapid reduction of inventory." Defendants claimed this was necessitated by the continued over-inflation of overall channel inventories as demand in China for Gardasil had "not recovered to the level we had expected."  Following this news, Merck's common stock declined dramatically. From a closing market price of $99.79 per share on February 3, 2025, Merck's stock price fell to $90.74 per share on February 4, 2025, a decline of more than 9% in the span of just a single day. WHAT'S NEXT? If you suffered a loss in Merck during the relevant time frame, you have until April 14, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP

Related News